Ignite Creation Date:
2024-05-06 @ 10:45 AM
Last Modification Date:
2024-10-26 @ 12:35 PM
Study NCT ID:
NCT03344835
Status:
RECRUITING
Last Update Posted:
2024-01-23
First Post:
2017-11-14
Brief Title:
Hong Kong Prostate Cancer Study Group Database
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
A Comprehensive Assessment of the Physical and Biological Effects of Patients With Prostate Cancer in Hong Kong
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prostate cancer PCa is ranked 3rd in annual incidence of male cancer and ranked 5th for cancer-related death in men in Hong Kong which accounts for about 91 deaths per 100000 men in 2011 Its incidence is rising rapidly almost tripled in the past 10 years In Hong Kong the two main screening methods for PCa are digital rectal examination DRE and serum prostate-specific antigen PSA level blood test and the gold standard of diagnosis of PCa is transrectal ultrasound TRUS with prostate biopsy
For those who diagnosed with PCa there are different kinds of managements depending on patients age group and disease stage Watchful waiting is for older patients who presents with low-risk prostate cancer And active surveillance is applicable to patients who are eligible for potentially curative management While radiotherapy or radical prostatectomy are recommended as curative management for early stage PCa androgen deprivation therapy ADT is the main treatment modality for advanced or recurrent prostate cancer Advanced prostate cancer that recurrence is called castration refractory prostate cancer CRPC There are many new agents including second line hormonal therapy chemotherapy androgen biosynthesis inhibitors immunotherapy bone targeting agents etc available for the further management
In this study investigators would like to establish a local prostate cancer registry to facilitate the collection of clinical information and outcomes of prostate cancer management Hopefully this registry can provide information regarding the epidemiology natural history and treatment outcomes of local prostate cancer The information would be helpful for research public education health care planning and also international collaboration Ultimately patients and public would be benefited from these works
For those who diagnosed with PCa there are different kinds of managements depending on patients age group and disease stage Watchful waiting is for older patients who presents with low-risk prostate cancer And active surveillance is applicable to patients who are eligible for potentially curative management While radiotherapy or radical prostatectomy are recommended as curative management for early stage PCa androgen deprivation therapy ADT is the main treatment modality for advanced or recurrent prostate cancer Advanced prostate cancer that recurrence is called castration refractory prostate cancer CRPC There are many new agents including second line hormonal therapy chemotherapy androgen biosynthesis inhibitors immunotherapy bone targeting agents etc available for the further management
In this study investigators would like to establish a local prostate cancer registry to facilitate the collection of clinical information and outcomes of prostate cancer management Hopefully this registry can provide information regarding the epidemiology natural history and treatment outcomes of local prostate cancer The information would be helpful for research public education health care planning and also international collaboration Ultimately patients and public would be benefited from these works
Detailed Description:
The prostate gland is a clinically important male accessory sex gland and vital for its production of semen Prostate cancer PCa is ranked 3rd in annual incidence of male cancer and ranked 5th for cancer-related death in men in Hong Kong which accounts for about 91 deaths per 100000 men in 2011 Its incidence is rising rapidly almost tripled in the past 10 years Although this cancer is extremely rare before age 40 but the incidence increases with age as the elderly population continues to increase the impact of PCa on the mens health and also the burden on health care system will continue to rise In addition to age epidemiological data shows that race is also an important risk factor for prostate cancer African-American men have the highest rates of prostate cancer in the world For Asian populations native Chinese and Japanese showed the lowest prostate cancer rates though the incidence is rapidly increasing in the past decades
The two main screening methods for PCa are digital rectal examination DRE and serum prostate-specific antigen PSA level blood test DRE is an exam to check for growths or enlargement of the prostate gland A tumor in the prostate can often be felt as a hard nodule This may be done as a regular exam or check for the symptoms If problems are suspected DRE is usually done together with PSA which was first introduced to evaluate the possibility of present of PCa in 1987 A common PSA threshold for biopsy in Hong Kong and Asia is PSA level greater than 40 ngmL Despite the controversial of PSA and some newer markers for PSA diagnosis it is still the most common screening for PCa due to the low cost and simplicity
The gold standard of diagnosis of PCa is transrectal ultrasound TRUS with prostate biopsy During the procedure usually ten cores of biopsies will be taken and sent for pathological evaluation If any of the biopsies are found malignant Gleason score will be given and the stage of cancer will be determined
Unlike other malignancy PCa is characterized by its slow progression nature and even for metastatic disease the 5-year survival is up to 20 Therefore there will be different kinds of management for difference age group and disease stage active surveillance AS watchful waiting and treatments Watchful waiting is for older patients who presents with low-risk prostate cancer In these cases treatment is probably not suitable for them due to the old age and low effectiveness Contrasting watchful waiting AS is applicable to patients who are eligible for potentially curative management During AS PCa is closely monitored for signs of progression PSA blood test and DRE are usually administered at times along with a repeat biopsy of the prostate at one year and then at specific intervals thereafter If symptoms develop or if tests indicate the cancer is growing treatment will be necessary
For early stage of prostate cancer radiotherapy or radical prostatectomy are recommended as curative management The purpose of these treatments is to cure the disease Over 80 of patients were cured with no recurrence Currently robotic prostatectomy is the main surgical approach for localized prostate cancer with acceptable perioperative results Radiotherapy both external beam and brachytherapy are also standard therapy for prostate cancer The overall complication rate as reported from the Western literatures for both surgery and radiotherapy are quite low The final choice of treatment will largely depend on the join decision between physicians and patients
However for advanced or recurrent prostate cancer androgen deprivation therapy ADT is the main treatment modality While the effectiveness of ADT is well documented in the literature the adverse effect profile in Asian patients in particular to the cardiovascular system and bone metabolism was not well documented
Due to the continue changes in the behavior of prostate cancer cell under androgen deprivated environment advanced prostate cancer will eventually entered a stage of castration refractory prostate cancer CRPC Currently there are many new agents including second line hormonal therapy chemotherapy androgen biosynthesis inhibitors immunotherapy bone targeting agents etc available for the further management of these CRPC patients Unfortunately the clinical outcome and side effect profiles for further treatment for patients with in local Chinese population as well as in Asian population was still not that certain
Due to the continue changes in the behavior of prostate cancer cell under androgen deprived environment advanced prostate cancer will eventually entered a stage of castration refractory prostate cancer CRPC Currently there are many new agents including second line hormonal therapy chemotherapy androgen biosynthesis inhibitors immunotherapy bone targeting agents etc available for the further management of these CRPC patients Unfortunately the clinical outcome and side effect profiles for further treatment for patients with in local Chinese population as well as in Asian population was still not that certain
Facing the increase in clinical demand by the drastic increase in patient population together with the rapid development in various therapies for different stages of prostate cancer there is a need to have better understanding about the natural history clinical outcomes of various therapies for prostate cancer Therefore investigators would like to establish a local prostate cancer registry to facilitate the collection of clinical information and outcomes of prostate cancer management Hopefully this registry can provide information regarding the epidemiology natural history and treatment outcomes of local prostate cancer The information would be helpful for research public education health care planning and also international collaboration Ultimately patients and public would be benefited from these works
In this study both retrospective and prospective cohort study design will be adopted Patients diagnosed with prostate cancer from 2016 will be captured prospectively and those who diagnosed in or before 2015 will be captured retrospectively Patients diagnosed with prostate cancer in the hospitals under the New Territories East Cluster NTEC New Territories West Cluster NTWC will be identified in specialist clinics wards and during TRUS and then enrolled to the study This study will be conducted by observation no intervention article is used The time of diagnosis of prostate cancer will be set as baseline of that subject All the demographic and medical background will be traced back All patients will be followed up every 6 months and thereafter During the follow-up patients medical status including survival cancer status treatment complications will be captured from the medical records
The two main screening methods for PCa are digital rectal examination DRE and serum prostate-specific antigen PSA level blood test DRE is an exam to check for growths or enlargement of the prostate gland A tumor in the prostate can often be felt as a hard nodule This may be done as a regular exam or check for the symptoms If problems are suspected DRE is usually done together with PSA which was first introduced to evaluate the possibility of present of PCa in 1987 A common PSA threshold for biopsy in Hong Kong and Asia is PSA level greater than 40 ngmL Despite the controversial of PSA and some newer markers for PSA diagnosis it is still the most common screening for PCa due to the low cost and simplicity
The gold standard of diagnosis of PCa is transrectal ultrasound TRUS with prostate biopsy During the procedure usually ten cores of biopsies will be taken and sent for pathological evaluation If any of the biopsies are found malignant Gleason score will be given and the stage of cancer will be determined
Unlike other malignancy PCa is characterized by its slow progression nature and even for metastatic disease the 5-year survival is up to 20 Therefore there will be different kinds of management for difference age group and disease stage active surveillance AS watchful waiting and treatments Watchful waiting is for older patients who presents with low-risk prostate cancer In these cases treatment is probably not suitable for them due to the old age and low effectiveness Contrasting watchful waiting AS is applicable to patients who are eligible for potentially curative management During AS PCa is closely monitored for signs of progression PSA blood test and DRE are usually administered at times along with a repeat biopsy of the prostate at one year and then at specific intervals thereafter If symptoms develop or if tests indicate the cancer is growing treatment will be necessary
For early stage of prostate cancer radiotherapy or radical prostatectomy are recommended as curative management The purpose of these treatments is to cure the disease Over 80 of patients were cured with no recurrence Currently robotic prostatectomy is the main surgical approach for localized prostate cancer with acceptable perioperative results Radiotherapy both external beam and brachytherapy are also standard therapy for prostate cancer The overall complication rate as reported from the Western literatures for both surgery and radiotherapy are quite low The final choice of treatment will largely depend on the join decision between physicians and patients
However for advanced or recurrent prostate cancer androgen deprivation therapy ADT is the main treatment modality While the effectiveness of ADT is well documented in the literature the adverse effect profile in Asian patients in particular to the cardiovascular system and bone metabolism was not well documented
Due to the continue changes in the behavior of prostate cancer cell under androgen deprivated environment advanced prostate cancer will eventually entered a stage of castration refractory prostate cancer CRPC Currently there are many new agents including second line hormonal therapy chemotherapy androgen biosynthesis inhibitors immunotherapy bone targeting agents etc available for the further management of these CRPC patients Unfortunately the clinical outcome and side effect profiles for further treatment for patients with in local Chinese population as well as in Asian population was still not that certain
Due to the continue changes in the behavior of prostate cancer cell under androgen deprived environment advanced prostate cancer will eventually entered a stage of castration refractory prostate cancer CRPC Currently there are many new agents including second line hormonal therapy chemotherapy androgen biosynthesis inhibitors immunotherapy bone targeting agents etc available for the further management of these CRPC patients Unfortunately the clinical outcome and side effect profiles for further treatment for patients with in local Chinese population as well as in Asian population was still not that certain
Facing the increase in clinical demand by the drastic increase in patient population together with the rapid development in various therapies for different stages of prostate cancer there is a need to have better understanding about the natural history clinical outcomes of various therapies for prostate cancer Therefore investigators would like to establish a local prostate cancer registry to facilitate the collection of clinical information and outcomes of prostate cancer management Hopefully this registry can provide information regarding the epidemiology natural history and treatment outcomes of local prostate cancer The information would be helpful for research public education health care planning and also international collaboration Ultimately patients and public would be benefited from these works
In this study both retrospective and prospective cohort study design will be adopted Patients diagnosed with prostate cancer from 2016 will be captured prospectively and those who diagnosed in or before 2015 will be captured retrospectively Patients diagnosed with prostate cancer in the hospitals under the New Territories East Cluster NTEC New Territories West Cluster NTWC will be identified in specialist clinics wards and during TRUS and then enrolled to the study This study will be conducted by observation no intervention article is used The time of diagnosis of prostate cancer will be set as baseline of that subject All the demographic and medical background will be traced back All patients will be followed up every 6 months and thereafter During the follow-up patients medical status including survival cancer status treatment complications will be captured from the medical records
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None